Verve Therapeutics, Inc. financial data

Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2025 - 14 May 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1238% % -25%
Debt-to-equity 30% % 9%
Return On Equity -36% % 4.1%
Return On Assets -28% % 5.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 89,143,237 shares 6.2%
Common Stock, Shares, Outstanding 88,796,578 shares 5.9%
Entity Public Float $345,200,000 USD -63%
Common Stock, Value, Issued $89,000 USD 6%
Weighted Average Number of Shares Outstanding, Basic 88,795,827 shares 6.8%
Weighted Average Number of Shares Outstanding, Diluted 88,795,827 shares 6.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $210,429,000 USD 13%
General and Administrative Expense $57,636,000 USD 12%
Operating Income (Loss) $208,452,000 USD 6%
Nonoperating Income (Expense) $27,768,000 USD 9.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $180,684,000 USD 8%
Income Tax Expense (Benefit) $322,000 USD -15%
Net Income (Loss) Attributable to Parent $181,006,000 USD 8%
Earnings Per Share, Basic -2 USD/shares 26%
Earnings Per Share, Diluted -2 USD/shares 26%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $96,554,000 USD -33%
Marketable Securities, Current $400,523,000 USD -13%
Cash, Cash Equivalents, and Short-term Investments $497,100,000 USD -18%
Assets, Current $511,650,000 USD -18%
Property, Plant and Equipment, Net $18,457,000 USD -12%
Operating Lease, Right-of-Use Asset $76,217,000 USD -8.8%
Other Assets, Noncurrent $3,065,000 USD 13%
Assets $614,163,000 USD -16%
Accounts Payable, Current $5,352,000 USD 76%
Accrued Liabilities, Current $17,053,000 USD 3%
Liabilities, Current $51,981,000 USD 66%
Operating Lease, Liability, Noncurrent $58,120,000 USD -8.4%
Other Liabilities, Noncurrent $70,000 USD -58%
Liabilities $140,650,000 USD -5.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax $393,000 USD
Retained Earnings (Accumulated Deficit) $774,047,000 USD -31%
Stockholders' Equity Attributable to Parent $473,513,000 USD -19%
Liabilities and Equity $614,163,000 USD -16%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $27,845,000 USD 35%
Net Cash Provided by (Used in) Investing Activities $48,168,000 USD -16%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 88,796,578 shares 5.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $76,006,000 USD -23%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $101,328,000 USD -32%
Deferred Tax Assets, Valuation Allowance $228,825,000 USD 33%
Deferred Tax Assets, Gross $251,225,000 USD 28%
Operating Lease, Liability $68,636,000 USD -6.8%
Depreciation $6,837,000 USD 15%
Payments to Acquire Property, Plant, and Equipment $1,224,000 USD 183%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $180,113,000 USD 8.6%
Lessee, Operating Lease, Liability, to be Paid $92,671,000 USD -10%
Property, Plant and Equipment, Gross $37,281,000 USD 13%
Operating Lease, Liability, Current $10,516,000 USD 2.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two $11,211,000 USD 0.01%
Lessee, Operating Lease, Liability, to be Paid, Year One $12,212,000 USD 12%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $24,035,000 USD -19%
Lessee, Operating Lease, Liability, to be Paid, Year Three $11,534,000 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards $57,936,000 USD 13%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $11,868,000 USD 0%
Operating Lease, Payments $2,717,000 USD 2.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $44,088,000 USD 18%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%